PL1951227T3 - Zastosowania pimobendanu do leczenia bezobjawowej(utajonej) niewydolności serca - Google Patents
Zastosowania pimobendanu do leczenia bezobjawowej(utajonej) niewydolności sercaInfo
- Publication number
- PL1951227T3 PL1951227T3 PL06829958T PL06829958T PL1951227T3 PL 1951227 T3 PL1951227 T3 PL 1951227T3 PL 06829958 T PL06829958 T PL 06829958T PL 06829958 T PL06829958 T PL 06829958T PL 1951227 T3 PL1951227 T3 PL 1951227T3
- Authority
- PL
- Poland
- Prior art keywords
- pimobendan
- occult
- asymptomatic
- treatment
- heart failure
- Prior art date
Links
- 206010019280 Heart failures Diseases 0.000 title 1
- 229960002164 pimobendan Drugs 0.000 title 1
- GLBJJMFZWDBELO-UHFFFAOYSA-N pimobendane Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=C(C=3C(CC(=O)NN=3)C)C=C2N1 GLBJJMFZWDBELO-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05110689 | 2005-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1951227T3 true PL1951227T3 (pl) | 2017-09-29 |
Family
ID=37744668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06829958T PL1951227T3 (pl) | 2005-11-14 | 2006-11-08 | Zastosowania pimobendanu do leczenia bezobjawowej(utajonej) niewydolności serca |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20070112010A1 (enExample) |
| EP (2) | EP1951227B1 (enExample) |
| JP (1) | JP5312034B2 (enExample) |
| CN (2) | CN101309685A (enExample) |
| AR (1) | AR056800A1 (enExample) |
| AU (1) | AU2006310997B2 (enExample) |
| CA (1) | CA2629367C (enExample) |
| DK (1) | DK1951227T3 (enExample) |
| ES (1) | ES2631879T3 (enExample) |
| HU (1) | HUE033546T2 (enExample) |
| PL (1) | PL1951227T3 (enExample) |
| TW (1) | TW200735874A (enExample) |
| WO (1) | WO2007054514A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004011512B4 (de) | 2004-03-08 | 2022-01-13 | Boehringer Ingelheim Vetmedica Gmbh | Pharmazeutische Zubereitung enthaltend Pimobendan |
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| FI20040674A0 (fi) | 2004-05-12 | 2004-05-12 | Orion Corp | Menetelmä tromboembolisten sairauksien estoon |
| EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| CA2723372A1 (en) * | 2008-05-05 | 2009-11-12 | University Of Rochester | Methods and compositions for the treatment or prevention of pathological cardiac remodeling and heart failure |
| EP2702987A1 (en) | 2008-11-25 | 2014-03-05 | Boehringer Ingelheim Vetmedica GmbH | Phosphodiesterase type III (PDE III) inhibitors or Ca2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy |
| NL1037569C2 (en) * | 2009-12-18 | 2011-06-21 | Eurovet Animal Health B V | Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use. |
| EP2825159B1 (en) * | 2012-03-15 | 2022-06-22 | Boehringer Ingelheim Vetmedica GmbH | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
| EP3865120B1 (en) | 2013-07-19 | 2025-06-25 | Boehringer Ingelheim Vetmedica GmbH | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
| WO2015082389A1 (en) | 2013-12-04 | 2015-06-11 | Boehringer Ingelheim Vetmedica Gmbh | Improved pharmaceutical compositions of pimobendan |
| US10537570B2 (en) * | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
| PT3439660T (pt) * | 2016-06-01 | 2024-07-18 | Boehringer Ingelheim Vetmedica Gmbh | Utilização de pimobendan para a redução do tamanho do coração e o retardamento do início de sintomas clínicos em doentes com insuficiência cardíaca assintomática devido a doença da válvula mitral |
| WO2022073954A1 (en) | 2020-10-08 | 2022-04-14 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan in the anaesthesia of non-human mammals |
| AU2024276892A1 (en) | 2023-05-24 | 2025-10-16 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES482789A0 (es) | 1978-08-25 | 1980-12-01 | Thomae Gmbh Dr K | Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona |
| GB8400863D0 (en) * | 1984-01-13 | 1984-02-15 | Smith Kline French Lab | Chemical compounds |
| ES2031821T3 (es) * | 1985-10-17 | 1993-01-01 | Smith Kline & French Laboratories Limited | Procedimiento para preparar derivados de 4(4-oxo-1,4-dihidropiridin-1-il)fenilo. |
| US4868182A (en) | 1986-11-05 | 1989-09-19 | Merrell Dow Pharmaceuticals Inc. | Enhancement of prazosin |
| DE3804490A1 (de) * | 1988-02-12 | 1989-08-24 | Heumann Pharma Gmbh & Co | Substituierte 6-phenyldihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| GB8824458D0 (en) | 1988-10-19 | 1988-11-23 | Orion Yhtymae Oy | Substituted pyridazinones |
| GB8903130D0 (en) | 1989-02-11 | 1989-03-30 | Orion Yhtymae Oy | Substituted pyridazinones |
| GB2251615B (en) | 1991-01-03 | 1995-02-08 | Orion Yhtymae Oy | (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile |
| DE60237696D1 (de) * | 2001-08-01 | 2010-10-28 | Univ Utah | Am n-terminus trunkierte isoformen von zyklischen phosphodiesterasen pde3a |
| EP1579862A1 (en) * | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
-
2006
- 2006-11-08 CN CNA2006800424125A patent/CN101309685A/zh active Pending
- 2006-11-08 JP JP2008540580A patent/JP5312034B2/ja active Active
- 2006-11-08 ES ES06829958.5T patent/ES2631879T3/es active Active
- 2006-11-08 AU AU2006310997A patent/AU2006310997B2/en active Active
- 2006-11-08 EP EP06829958.5A patent/EP1951227B1/en active Active
- 2006-11-08 PL PL06829958T patent/PL1951227T3/pl unknown
- 2006-11-08 HU HUE06829958A patent/HUE033546T2/hu unknown
- 2006-11-08 EP EP17165100.3A patent/EP3210605A1/en not_active Withdrawn
- 2006-11-08 CA CA2629367A patent/CA2629367C/en active Active
- 2006-11-08 DK DK06829958.5T patent/DK1951227T3/en active
- 2006-11-08 CN CN201210144177XA patent/CN102784394A/zh active Pending
- 2006-11-08 WO PCT/EP2006/068231 patent/WO2007054514A2/en not_active Ceased
- 2006-11-10 AR ARP060104928A patent/AR056800A1/es not_active Application Discontinuation
- 2006-11-13 TW TW095141963A patent/TW200735874A/zh unknown
- 2006-11-14 US US11/559,467 patent/US20070112010A1/en not_active Abandoned
-
2010
- 2010-07-07 US US12/831,657 patent/US20100273807A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3210605A1 (en) | 2017-08-30 |
| JP2009515927A (ja) | 2009-04-16 |
| TW200735874A (en) | 2007-10-01 |
| JP5312034B2 (ja) | 2013-10-09 |
| CN102784394A (zh) | 2012-11-21 |
| CA2629367A1 (en) | 2007-05-18 |
| US20070112010A1 (en) | 2007-05-17 |
| DK1951227T3 (en) | 2017-07-10 |
| AU2006310997B2 (en) | 2013-01-10 |
| US20100273807A1 (en) | 2010-10-28 |
| AR056800A1 (es) | 2007-10-24 |
| CA2629367C (en) | 2016-05-03 |
| HUE033546T2 (hu) | 2017-12-28 |
| ES2631879T3 (es) | 2017-09-05 |
| WO2007054514A2 (en) | 2007-05-18 |
| EP1951227B1 (en) | 2017-04-12 |
| WO2007054514A3 (en) | 2007-09-07 |
| EP1951227A2 (en) | 2008-08-06 |
| CN101309685A (zh) | 2008-11-19 |
| AU2006310997A1 (en) | 2007-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200806510B (en) | Heterobicyclic sulfonamide derivatives for the treatment of diabetes | |
| IL191832A0 (en) | Pyridiazinone derivatives for the treatment of tumours | |
| EP1901635A4 (en) | SUPPORT FOR PATIENT | |
| IL194076A0 (en) | Imidazolothiazole compounds for the treatment of disease | |
| ZA200710192B (en) | Substituted arylpyrazoles for use against parasitites | |
| IL192395A0 (en) | Modified lysine-mimetic compounds | |
| IL190920A0 (en) | Compounds for the treatment of metabolic disorders | |
| IL187279A0 (en) | Hydantoin compounds | |
| PL1951227T3 (pl) | Zastosowania pimobendanu do leczenia bezobjawowej(utajonej) niewydolności serca | |
| IL186282A0 (en) | Benzimidazole compound | |
| EP1720863A4 (en) | HETEROARYLAMINOPYRAZOLE DERIVATIVES FOR TREATING DIABETES | |
| GB0518361D0 (en) | Therapeutic compounds | |
| ZA200708033B (en) | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | |
| ZA200805159B (en) | Imidazole derivatives for the treatment of gastrointestinal disorders | |
| EP1880721A4 (en) | MEANS FOR IMPROVING CIRCULAR DISORDER | |
| PL1945243T3 (pl) | Zastosowanie kalcytoniny w leczeniu rzs | |
| GB0512770D0 (en) | Imaging compounds | |
| EP1950209A4 (en) | TREATMENT AGENT FOR CIRCULATORY INSUFFICIENCY | |
| ME01609B (me) | Roflumilast za liječenje pulmonarne hipertenzije | |
| GB0400802D0 (en) | Compounds for the treatment of disease | |
| EP1750698A4 (en) | 5-ANILINO-4-HETEROARYLPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | |
| PL372356A1 (pl) | Nowe związki, pochodne kwasu 3-fenylopropionowego | |
| IL183036A0 (en) | Biomarker for heart failure | |
| ZA200608015B (en) | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | |
| GB0604775D0 (en) | Use Of Substituted Benzimidazole Sulfonamide Compounds For The Treatment Of Food Related Disorders |